2 results match your criteria: "New York9Weill Cornell Medical College[Affiliation]"
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
JAMA Oncol
January 2016
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York6Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering, New York, New York9Weill Cornell Medical College, New York, New York.
Importance: Tumor genetic sequencing identifies potentially targetable genetic alterations with therapeutic implications. Analysis has concentrated on detecting tumor-specific variants, but recognition of germline variants may prove valuable as well.
Objective: To estimate the burden of germline variants identified through routine clinical tumor sequencing.
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
JAMA Oncol
July 2015
Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, New York9Weill-Cornell Medical College, New York, New York.
Importance: The anti-PD-1 therapeutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma. The activity of nivolumab in subgroups of patients with tumors which have wild-type BRAF kinase vs patients with tumors having mutant BRAF has not systematically been explored in a large dataset.
Objective: To evaluate the efficacy and safety of nivolumab in patients with wild-type BRAF and mutant BRAF metastatic melanoma.